232 related articles for article (PubMed ID: 26552829)
1. Synthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA.
Wilner SE; Levy M
Methods Mol Biol; 2016; 1380():211-24. PubMed ID: 26552829
[TBL] [Abstract][Full Text] [Related]
2. pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis.
Jia Z; Gong Y; Pi Y; Liu X; Gao L; Kang L; Wang J; Yang F; Tang J; Lu W; Li Q; Zhang W; Yan Z; Yu L
Mol Pharm; 2018 Jan; 15(1):53-62. PubMed ID: 29148802
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
4. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
5. Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model.
Jansen MAA; Klausen LH; Thanki K; Lyngsø J; Skov Pedersen J; Franzyk H; Nielsen HM; van Eden W; Dong M; Broere F; Foged C; Zeng X
Eur J Pharm Biopharm; 2019 Sep; 142():38-48. PubMed ID: 31199978
[TBL] [Abstract][Full Text] [Related]
6. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype.
Conceição M; Mendonça L; Nóbrega C; Gomes C; Costa P; Hirai H; Moreira JN; Lima MC; Manjunath N; Pereira de Almeida L
Biomaterials; 2016 Mar; 82():124-37. PubMed ID: 26757259
[TBL] [Abstract][Full Text] [Related]
7. Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.
Scognamiglio I; Di Martino MT; Campani V; Virgilio A; Galeone A; Gullà A; Gallo Cantafio ME; Misso G; Tagliaferri P; Tassone P; Caraglia M; De Rosa G
Biomed Res Int; 2014; 2014():217365. PubMed ID: 24683542
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a DoE based approach for comprehensive modelling of the effect of lipid nanoparticle composition on nucleic acid delivery.
Qin Y; Walters AA; Rouatbi N; Wang JT; Abdel-Bar HM; Al-Jamal KT
Biomaterials; 2023 Aug; 299():122158. PubMed ID: 37243988
[TBL] [Abstract][Full Text] [Related]
9. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of PLGA-Lipid Hybrid Nanoparticles for siRNA Delivery Using the Emulsion Method PLGA-PEG-Lipid Nanoparticles for siRNA Delivery.
Wang L; Griffel B; Xu X
Methods Mol Biol; 2017; 1632():231-240. PubMed ID: 28730443
[TBL] [Abstract][Full Text] [Related]
11. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
12. Aptamer mediated siRNA delivery.
Chu TC; Twu KY; Ellington AD; Levy M
Nucleic Acids Res; 2006 Jun; 34(10):e73. PubMed ID: 16740739
[TBL] [Abstract][Full Text] [Related]
13. Cancer-targeted Nucleic Acid Delivery and Quantum Dot Imaging Using EGF Receptor Aptamer-conjugated Lipid Nanoparticles.
Kim MW; Jeong HY; Kang SJ; Choi MJ; You YM; Im CS; Lee TS; Song IH; Lee CG; Rhee KJ; Lee YK; Park YS
Sci Rep; 2017 Aug; 7(1):9474. PubMed ID: 28842588
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach.
Coutinho MF; Santos JI; S Mendonça L; Matos L; Prata MJ; S Jurado A; Pedroso de Lima MC; Alves S
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785133
[TBL] [Abstract][Full Text] [Related]
15. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
Bagalkot V; Gao X
ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
Bartlett DW; Davis ME
Bioconjug Chem; 2007; 18(2):456-68. PubMed ID: 17326672
[TBL] [Abstract][Full Text] [Related]
17. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer.
de Almeida CEB; Alves LN; Rocha HF; Cabral-Neto JB; Missailidis S
Int J Pharm; 2017 Jun; 525(2):334-342. PubMed ID: 28373101
[TBL] [Abstract][Full Text] [Related]
18. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
19. Targeted gene delivery with noncovalent electrostatic conjugates of sgc-8c aptamer and polyethylenimine.
Shahidi-Hamedani N; Shier WT; Moghadam Ariaee F; Abnous K; Ramezani M
J Gene Med; 2013; 15(6-7):261-9. PubMed ID: 23794147
[TBL] [Abstract][Full Text] [Related]
20. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
Wang XL; Wang QQ; Song HF
Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
